Curanex Pharmaceuticals Inc. recently reported its quarterly results for the period ending June 30, 2025. The company did not generate any revenue during the three months ended June 30, 2025, which aligns with its ongoing focus on the development of botanical drug candidates and achieving clinical and regulatory milestones. Operating expenses saw an increase, with general and administrative expenses rising to $57,658 for the three months ended June 30, 2025, compared to $44,200 for the same period in 2024. This increase is attributed mainly to the ongoing costs related to the company's preparation for an initial public offering $(IPO)$ and maintaining readiness for operating as a public company. For the six-month period ending June 30, 2025, Curanex also reported no revenue, consistent with its strategic focus. General and administrative expenses for this period increased to $195,110 from $124,401 in the same period in 2024, again primarily due to IPO-related costs. The company has stated that it anticipates generating revenue only upon the successful commercialization of its product candidates or through strategic licensing agreements, though there is no assurance regarding the timing or likelihood of these events.